Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 16/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10459278 | 0.88 | BCDIN3D (0.35) | CYP2D6FAAHCCNT1GSK3BCDK9 | |
| SCHEMBL10459320 | 0.88 | ALDH1A1 (0.37) | CCNT1GSK3BCDK9 | |
| SCHEMBL10458869 | 0.86 | MAPK14 (0.36) | CCNT1GSK3BCDK9 | |
| SCHEMBL10459433 | 0.83 | PRKCQ (0.33) | FAAHCCNT1GSK3BCDK9 | |
| SCHEMBL10458868 | 0.82 | CCNT1 (0.37) | DYRK1ACCNT1GSK3BCDK9 | |
| SCHEMBL10459366 | 0.81 | PRKCA (0.40) | DYRK1ACCNT1GSK3BCDK9 | |
| SCHEMBL10457547 | 0.81 | CYP2D6 (0.53) | CYP2D6FAAHDYRK1ACCNT1GSK3B | |
| SCHEMBL10459336 | 0.79 | CDK2 (0.35) | CYP2D6DYRK1ACCNT1GSK3BCDK9 | |
| SCHEMBL10457572 | 0.77 | KDM4E (0.42) | CYP2D6DYRK1ACCNT1CDK9 | |
| SCHEMBL10459466 | 0.77 | CDK2 (0.34) | CYP2D6CCNT1GSK3BCDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9137973-B2 | Pyrazolopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-09-22 | — | — | US | disclosed |
| US-9137973-B2 | Pyrazolopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-09-22 | — | — | US | disclosed |
| US-9029546-B2 | Pyrazolopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029546-B2 | Pyrazolopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-05-12 | — | — | US | disclosed |
| US-20140148434-A1 | PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-05-29 | — | — | US | disclosed |
| US-20140148434-A1 | PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-05-29 | — | — | US | disclosed |
| US-20120184524-A1 | PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148434-A1 | PYRAZOLOPYRIDINE KINASE INHIBITORS | MAP3K5, MAP3K20, MAP3K1 | CYP2D6 1589/4885FAAH 3324/4885DYRK1A 510/4885 |
| US-20120184524-A1 | PYRAZOLOPYRIDINE KINASE INHIBITORS | MAP3K5, MAP3K20, MAP3K1 | CYP2D6 1589/4885FAAH 3324/4885DYRK1A 510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.